Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma

Prognostic significance of [18F]fluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: a retrospective analysis

“…Our findings are in contrast to classical Hodgkin lymphoma (7,11,12) and B-cell non-Hodgkin lymphoma (5,6) where a negative pre-transplantation FDG-PET has been consistently prognostic of PFS and/or OS. It is important to note, however, that as a retrospective study, this analysis was limited by the heterogeneity of the pre-transplantation chemotherapy received, and by the inclusion of both autologous and allogeneic transplantations with several different conditioning regimens.…”

“…In other aggressive lymphomas such as diffuse large B-cell lymphoma and Hodgkin lymphoma, PET performed after salvage chemotherapy has been shown to have important prognostic implications for risk of relapse after subsequent SCT (5,6,7). Although obtaining a pre-transplantation FDG-PET is routine clinical practice, the ability of FDG-PET to predict long-term post-transplantation outcomes in PTCL has not been established.…”

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

“…Indeed, the best outcomes of HD-ASCT have been reported in patients who are negative on FDG-PET imaging before HD-ASCT. 27 The outcome of salvage therapy has changed in the rituximab era. For example, Martin et al reported the results of the GEL/TAMO study, which evaluated the influence of prior rituximab use in response rates of rituximab plus etoposide, methylprednisolone, cytarabine, cisplatin (R-ESHAP) as salvage therapy for patients with relapsed or refractory DLBCL.…”

Fluorodeoxyglucose PET-CT Findings Following Bone Marrow Harvesting

“…FDG PET and PET-CT can be used to predict outcome before and after treatment of lymphoma patients with autologous stem cell transplantation. [34]…”